MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

Burnout among physicians and residents continues to grow, with six out of 10 reporting these feelings, along with continued ...

Contributors SM, A-EC, MK and JG-A conceived the study design, analysed the results ... Belgian Science Policy Office, National Fund for Scientific Research, Estonia: Estonian Science Foundation, ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sees 2025 non-GAAP R&D $5.00B-$5.20B. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Published first ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

Regeneron is the second pharma group to sign ... Those can be used for "natural history analysis, trial design, cohort formation, and data analysis," according to the partners.